Liposomal cytarabine is currently being tested clinically as an alternative to intrathecal (IT) methotrexate (MTX) for preventing relapse within the central nervous system among patients with acute lymphoblastic leukemia. To compare the toxicity and cognitive deficits caused by IT MTX versus liposomal cytarabine, juvenile Long Evans rats were treated with IT injections of MTX 1 mg/kgÂ 4 doses over 8 days, or liposomal cytarabine 0.8 mg once. Mean concentrations of free cytarabine in cerebrospinal fluid remained above the cytotoxic threshold of 0.4 mM for 2 weeks after dosing. Animals treated with liposomal cytarabine exhibited normal recognition and spatial memory 4 weeks after injection. In contrast, exposure to IT MTX led to impaired cognitive function. In addition, mean hematocrit on day 11 was significantly lower in the MTX-treated animals (30.8%; 95% confidence interval, 27.0%-34.7%; n = 6) compared with that in the liposomal cytarabine-treated animals (39.5%; 95% confidence interval, 38.4%-40.6%; n = 6; P < 0.0001). Our data suggest that liposomal cytarabine induces fewer neurocognitive deficits and less acute hematologic toxicity compared with IT MTX. Liposomal cytarabine may therefore have therapeutic advantages over IT MTX, if it is equally effective in preventing relapse.
M ost children with acute lymphoblastic leukemia (ALL) are cured with current therapeutic regimens, which include prophylactic intrathecal (IT) chemotherapy to prevent relapse within the central nervous system (CNS). However, ALL survivors often suffer from measurable neurocognitive deficits as a result of CNS-directed therapy. [1] [2] [3] [4] [5] Methotrexate (MTX) is a standard component of CNS prophylaxis. Administered both intrathecally and as a highdose intravenous infusion, its use has led to a dramatic reduction in CNS relapse rates. We and others have demonstrated that MTX induces structural and metabolic changes in the CNS, as well as persistent neurocognitive dysfunction in human and animal models relative to shaminjected controls. [6] [7] [8] [9] [10] [11] As both the physical and psychosocial quality of life is affected by the individual's cognitive functioning, it is important to address this therapeutic problem. 12 This study was conducted to compare the systemic toxicities and cognitive sequelae that result from IT MTX versus that of liposomal cytarabine, when both are administered at clinically relevant doses and schedules. The sustained-release formulation of cytarabine, liposomal cytarabine, is effective in the relapse setting. 13 After IT administration, cytotoxic cytarabine levels are observed in the cerebrospinal fluid (CSF) for at least 1 week. 14 Treatment with liposomal cytarabine can cause chemical arachnoiditis, but this is a side effect that can be prevented by concomitant administration of dexamethasone. 13, [15] [16] [17] [18] Neither cognitive deficits nor marrow suppression are commonly described after IT cytarabine, suggesting that liposomal cytarabine will also offer these therapeutic advantages over IT MTX.
MATERIALS AND METHODS

Experimental Design
All experiments were approved by the Animal Institute and Use Committee of the Albert Einstein College of Medicine (Bronx, NY) and were conducted following the "Guide for the Care and Use of Laboratory Animals." Juvenile (4 wk old) Long Evans rats were obtained from Charles River Laboratories (Wilmington, MA) and randomly divided into 3 treatment arms with an equal distribution of male and female animals. The rats were housed in groups of 2 or 3 with a 12/12 hours light/dark cycle and ad libitum access to food (LabDiet 5001) and water. Treatment started 1 week after arrival, when the animals were 5 weeks old. Each treatment arm was designed to mimic a schedule used clinically to prevent or treat CNS relapse of ALL (Fig. 1) . 13, 15, 19 A control cohort was given sham injections of artificial CSF (aCSF, Na + 150 mM, K + 3 mM, Ca 2 + 1.4 mM, Mg 2 + 0.8 mM, P 1.0 mM, Cl À 155 mM) in volumes equivalent to liposomal cytarabine injections. MTX was administered at a dose of 1 mg/kg diluted in a CSF, at a final volume of 30 to 60 mL, 4 times in a 2-week period. Liposomal cytarabine was given once, at a dose of 0.8 mg (80 mL) along with daily intraperitoneal injections of 0.2 mg (1 mL) dexamethasone for 3 days to reduce the risk of acute arachnoiditis. 13, 20 MTX and control animals received 1 mL intraperitoneal phosphate-buffered saline on the same schedule. IT injections were carried out as previously described by transcutaneous cisterna magna puncture with a 25-G butterfly needle. 7 Correct insertion of the needle was verified by outflow of CSF, which was collected in isovolumetric amounts (ie, volume of CSF removed was equivalent to volume of drug to be administered) before IT injection. All animals were monitored for signs of acute toxicity under direct visualization for 1 hour after injection and subsequently on a daily basis for evidence of abnormal behaviors. Treatment conditions were replicated in 2 independent cohorts and a total of 118 rats were included in the study. The animals were excluded (n = 10) if death (n = 4) or any serious health conditions (eg, severe dental malocclusion) occurred during the time span (13 wk) of the experiments.
Weight was recorded weekly starting on the day of treatment. CSF was collected before each IT treatment, plus on days 7 and 14, and directly put on ice. Approximately 5% of collected specimens were visibly contaminated by blood and were discarded. The samples were centrifuged to remove any cellular elements, and supernatants were stored at À751C until further analysis. Blood was collected from the ventral artery of the tail on day 11 and 14 after first IT treatment, using a 25-G needle, collecting volumes that varied from 0.3 to 0.6 mL. Blood was immediately placed in ethylenediaminetetraacetic acid tubes and stored at + 41C until further analysis. Behavioral tests were carried out at 4 and 11 weeks after first IT treatment ( Fig. 1) .
High-performance Liquid Chromatography (HPLC)
Concentrations of free cytarabine in CSF were measured by HPLC using a Waters 2695 separation module equipped with a U Bondapak C18 analytical column (3.9 Â150 mm). After trichloroacetic acid precipitation of protein, 25 mL of CSF was injected, using a mobile phase of 0.1 M KH 2 PO 4 /methanol buffer, pH 3.1. Absorbance was monitored with a PDA detector at 272 nm. Cytarabine concentrations were quantified on the basis of an external calibration method with known standards (Sigma Aldrich, St Louis, MO). The lower limit of detection was 0.08 mM.
Behavioral Assessments
The open field was used to assess locomotor activity, exploratory, and anxiety-like behavior. Briefly, the rats were free to explore the testing arena (69Â 69 cm) for 6 minutes. Total track length was a measure of general activity level and time spent in the center zone (21 Â21 cm) related inversely to the degree of anxiety-like behavior. Activities were captured by digital camera and analyzed by Viewer software (Biobserver, Bonn, Germany).
Recognition and spatial memory are dependent on distinct aspects of working memory and were assessed with the novel object recognition (NOR) task and the novel object placement (OP) task, respectively, as previously described. 7, [21] [22] [23] These tasks utilize the natural preference of rodents to explore novels objects. Briefly, during training, animals were exposed to a pair of identical objects. After a defined retention interval in their home cages (30 to 180 min depending on the task), the rats were presented with 1 unmoved and 1 relocated object (OP) or 1 old and 1 NOR in a testing trial. Total activity, assessed by track length, and total object exploration times were recorded in seconds. Exploration was defined as any physical contact with the object (sniffing, whisking, or touching). Trials with total exploration time <4 seconds were excluded from analysis (< 2% of trials). A preference score was determined by the ratio of time exploring the relocated or novel object to total exploration time during the testing trial. For each cohort of identically treated animals, intact memory was demonstrated by a group mean preference score significantly higher than 55%. In our previous experience, animals with preference scores above 55% consistently demonstrate novel object preferences when retested. 6, 7, 10, 23 All animals were exposed to equal conditions regarding time of training, testing, and period of retention interval. The tester was blinded to treatment conditions.
Statistical Analysis
One-sample, 2-tailed t test was used to determine whether a cohort of identically treated rats showed mean preference scores that were statistically higher than 55%. Mean preference scores were compared with GraphPad Prism 6.07 (GraphPad Software, San Diego, CA), using 2-tailed t tests, and contingencies were analyzed by the Fisher exact test. Biochemical data were analyzed using 1-way After IT administration of 0.8 mg liposomal cytarabine, free cytarabine in CSF was measured by HPLC. Mean free cytarabine concentrations remained above 0.4 mM, levels that are known to be cytotoxic in vitro, 13, 24 for at least 2 weeks as shown in Figure 2 . No differences in pharmacokinetics were detected between male and female rats.
Absence of Gross Systemic Toxicity
Neither MTX nor liposomal cytarabine had impact on weight gain (Fig. 3) . There was no significant difference in mean growth ( ± SD) among female rats (aCSF 3.2 ± 1. Locomotor activity and anxiety-like behavior were assessed in the open field 4 weeks after the first IT injection. No differences were observed in total track length (aCSF 3544 ± 559.5 cm, n = 42; liposomal cytarabine 3431 ± 568.6 cm, n = 39; MTX 3372 ± 572.8 cm, n = 37) nor were there any indications of anxiety-like behavior, inversely related to the duration of time spent in the center zone of the testing arena, in any cohort (aCSF 13.6 ± 6.3 s, n = 42; liposomal cytarabine 13.6 ± 7.2 s, n = 39; MTX 14.9 ± 8.6 s, n = 37).
Neurocognitive Outcomes
No significant differences were observed between male and female animals in any neurocognitive outcome. Therefore, data for both sexes are combined in the remainder of the results presented here. As we have previously demonstrated, 6,7,10 animals treated with IT MTX showed impaired spatial memory (OP task) and recognition memory (NOR task) 4 weeks after injection, with mean preference scores that were not significantly greater than the "passing" criterion of 55% (OP: 56.1%; 95% confidence interval [CI], 51.2%-61.0%; t = 0.5; df = 36; n = 37; P > 0.05, NOR: 56.8%; 95% CI, 50.6%-62.9%; t = 0.6; df = 25; n = 26; P > 0.05). Partial recovery of neurocognitive function was observed 11 weeks after IT injection. At this time point, spatial memory remained impaired (Fig. 4) , but MTX-treated animals had a mean NOR preference score that was significantly >55% (61.7%; 95% CI, 57.4-66.0; t = 3.2; df = 36; n = 37; P < 0.05).
In contrast with the MTX-treated animals, those treated with liposomal cytarabine demonstrated intact spatial and recognition memory 4 weeks after injection.
Mean OP and NOR preference scores were significantly >55% pass criterion (OP: 63.1%; 95% CI, 58.1%-68.0%; t = 3.3; df = 38; n = 39; P < 0.05, NOR: 67.2%; 95% CI, 62.4%-72.0%; t = 5.3; df = 22; n = 23; P < 0.0001) (Fig. 5) . Eleven weeks after IT liposomal cytarabine, recognition memory remained intact, with a mean NOR preference score significantly >55% (63.7%; 95% CI, 60.2%-67.2%; t = 5.0; df = 38; n = 39; P < 0.0001, 1-sample 2-sided t test) (Fig. 4) . However, mean OP preference scores now indicated impaired spatial memory (55.8%; 95% CI, 52.0%-59.6%; t = 0.4; df = 38; n = 39; P > 0.05). At both the 4-and 11-week time points, the proportion of animals with impaired recognition or spatial memory tended to be greater among the cohort treated with IT MTX than among those treated with IT liposomal cytarabine (Fig. 4) . Although the trend was consistent at the 2 time points, these differences were not statistically significant by a Fisher exact test.
MTX But Not Liposomal Cytarabine Caused Transient Suppression of Hematopoiesis
Mean hematocrit ( ± SD) was significantly decreased at day 11 after administration of IT MTX (30.8% ± 3.7%; 95% CI, 27.0%-34.7%; n = 6) compared with that after administration of liposomal cytarabine (39.5% ± 1.1%; 95% CI, 38.4%-40.6%; n = 6; P < 0.0001) and that in controls (40.5% ± 1.1%; 95% CI, 34.4%-41.6%; n = 6; P < 0.0001) (Fig. 5) . Unfortunately, insufficient sample volumes were available at day 11 to measure complete blood counts.
Three days later, on day 14, complete blood counts were analyzed. Hematocrit had equalized in all treatment arms with mean hematocrit ( ± SD) of 38.3% ± 2.8%, n = 4; 39.3% ± 1.5, n = 4; and 39.8% ± 1.3, n = 4 (P > 0.05) in MTX, liposomal cytarabine, and aCSF-treated animals, respectively. Absolute reticulocytes ( ± SD) were significantly increased in the MTX-treated arm (552.3 ± 115.8Â10
DISCUSSION
Currently, MTX is the most frequently used chemotherapeutic drug for CNS-directed treatment in ALL. However, it has been associated with acute neurological and hematological toxicity and persistent cognitive impairments compared with controls in both human and animal models. 1, 3, 11, [25] [26] [27] IT administration of free cytarabine is already widely used either alone or as part of a triple IT therapy for patients with leukemia. Liposomal cytarabine is a slowrelease formulation of cytarabine that leads to prolonged cytotoxic activity after administration and thus reduces the need of frequent and burdensome IT injections, and risk of myelosuppression. Hence, liposomal cytarabine may offer potential advantages over MTX with regard to CNS prophylaxis. In this study, we demonstrated that liposomal cytarabine does not cause any detectable acute toxicity and, more importantly, that it induces less cognitive dysfunction than an equivalent course of IT MTX.
It is possible that liposomal cytarabine leads to a later onset of cognitive decline compared with IT MTX. Recognition memory remained normal among the liposomal cytarabine-treated animals at both time points; however, at the 11-week point we did observe an increase in the proportion showing impaired function. Similar increase in the OP task resulted in a shift from intact spatial memory at 4 weeks to impaired spatial memory by 11 weeks.
Nevertheless, the increases were not statistically significant, and in both tests at both time points, the proportion of animals demonstrating impaired memory was greater after IT MTX than after liposomal cytarabine.
Importantly, the finding of less cognitive deficits among animals treated with liposomal cytarabine was not due to subtherapeutic drug levels. Free cytarabine concentrations in CSF were maintained above a cytotoxic threshold of 0.4 mM for 2 weeks following injection of 0.8 mg liposomal cytarabine, which corresponds with findings in previous animal and human studies. 13, 16 These results further support the clinical utility of IT liposomal cytarabine for CNS prophylaxis, as duration of exposure to cytotoxic drug concentrations is a critical factor for cellcycle-specific antimetabolites like both cytarabine and MTX.
In addition to the deleterious effects on cognition, MTX can exert systemic toxicity when administered intrathecally, because of active transport from CSF to blood. 27,28 Although we did not measure serum MTX concentrations, we did observe suppression of hematopoiesis (anemia, followed by recovering reticulocytosis). Because IT MTX can exacerbate the systemic toxicity caused by oral or intravenous therapy, clinical protocols for childhood leukemia in the United States do not administer IT MTX concurrently with systemic MTX. The absence of hematopoietic suppression after IT liposomal cytarabine suggests that the use of this agent for CNS prophylaxis would facilitate the maintenance of systemic treatment intensity. It should be noted that the myelosuppressive effect of IT MTX may contribute to prevention of marrow relapse. The theoretical possibility that replacing IT MTX with liposomal cytarabine could increase risk of relapse should therefore be monitored carefully in clinical trials comparing the 2 approaches. Intercohort differences in treatment-induced neurocognitive impairments were a priori expected to be subtle. To increase our statistical power to detect the effects of each drug, the experiments were conducted in 2 independent cohorts, and the results shown here are the combined data sets. Our study was not powered to detect sex differences in susceptibility to treatment-induced memory deficits. Both male and female animals were included, as behavioral activity can be sex dependent. Nevertheless, we did not observe significant differences in cognitive performance between the 2 sexes. Finally, we acknowledge the potential confounder of systemic dexamethasone among the animals treated with liposomal cytarabine. Steroids can alter neurocognitive functioning directly through glucocorticoid receptors in the hippocampus. Alternatively, they may reduce treatment-induced cognitive dysfunction by inhibiting neuroinflammation. However, we felt its use was warranted in this study to model the clinical administration of liposomal cytarabine, which, unlike IT MTX, is typically administered concurrently with a systemic corticosteroid to prevent symptoms of chemical arachnoiditis. 20 Ongoing studies in our laboratory will assess the effects of repeated doses of liposomal cytarabine on cognitive function. In addition, we will compare the pathophysiological mechanisms triggered by IT administration of liposomal cytarabine versus MTX, including alterations in neurogenesis, white matter injury, and oxidative stress.
In conclusion, liposomal cytarabine induced less acute hematologic toxicity and decreased cognitive dysfunction relative to IT MTX in our animal model. These findings suggest that liposomal cytarabine may offer therapeutic advantages over IT MTX and support further clinical comparison of the efficacy and toxicity of these 2 agents for preventing CNS relapse among children with ALL. Behavioral performance in the novel object placement (OP) task and the novel object recognition (NOR) task at 4 and 11 weeks after first intrathecal (IT) treatment of 0.8 mg liposomal cytarabine (LC) (4 wk: OP, n = 39; NOR, n = 23; 11 wk: OP, n = 37; NOR, n = 39) or 1 mg/kg methotrexate (MTX) (4 wk: OP, n = 37; NOR, n = 26; 11 wk: OP, n = 37; NOR, n = 37). Graphs show combined data from both male and female rats. Each symbol represents 1 animal. Dotted line at preference score of 55% indicates the criterion for passing the test. The percentage of the whole treatment group who did not pass is indicated above the x-axis. Mean scores significantly above 55% are indicated with asterisk (1-sample 2-sided t test, *P < 0.05). In all tests, the proportion of liposomal cytarabine-treated animals who failed to show intact function was smaller than the proportion of methotrexate-treated animals.
